Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Pinnacle Associates Ltd.

Pinnacle Associates Ltd. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,926 shares of the biopharmaceutical company’s stock after selling 12,087 shares during the period. Pinnacle Associates Ltd. owned approximately 0.06% of Regeneron Pharmaceuticals worth $36,186,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of REGN. Vanguard Group Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock worth $5,966,767,000 after purchasing an additional 121,545 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Regeneron Pharmaceuticals by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock worth $1,379,467,000 after purchasing an additional 89,579 shares in the last quarter. Amundi raised its holdings in shares of Regeneron Pharmaceuticals by 3.4% during the 1st quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company’s stock valued at $979,794,000 after buying an additional 52,166 shares during the period. Goldman Sachs Group Inc. lifted its position in Regeneron Pharmaceuticals by 18.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock worth $724,984,000 after acquiring an additional 174,056 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in Regeneron Pharmaceuticals by 2.1% during the 1st quarter. American Century Companies Inc. now owns 722,467 shares of the biopharmaceutical company’s stock worth $458,211,000 after acquiring an additional 14,921 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $654.04 on Friday. The company has a quick ratio of 3.72, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $883.15. The stock’s 50 day moving average is $580.56 and its two-hundred day moving average is $564.66. The company has a market capitalization of $69.32 billion, a PE ratio of 15.66, a P/E/G ratio of 2.03 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.Regeneron Pharmaceuticals’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the previous year, the business earned $12.46 EPS. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is 8.43%.

Wall Street Analyst Weigh In

REGN has been the topic of several recent research reports. Citigroup boosted their price target on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a research report on Wednesday. Canaccord Genuity Group reissued a “buy” rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, October 23rd. Wells Fargo & Company boosted their price target on Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Bank of America boosted their price target on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the stock an “underperform” rating in a research report on Wednesday. Finally, UBS Group reissued a “neutral” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $813.78.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.